サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1564079

がん遺伝子治療の世界市場

Cancer Gene Therapy

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
がん遺伝子治療の世界市場
出版日: 2024年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がん遺伝子治療の世界市場は2030年までに88億米ドルに到達

2023年に23億米ドルと推定されるがん遺伝子治療の世界市場は、分析期間2023-2030年にCAGR 21.1%で成長し、2030年には88億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるがん性ウイルス療法は、CAGR 21.9%を記録し、分析期間終了時には43億米ドルに達すると予想されます。遺伝子導入療法分野の成長率は、分析期間中CAGR 15.7%と推定されます。

米国市場は6億1,540万米ドルと推定、中国はCAGR20.0％で成長予測

米国のがん遺伝子治療市場は、2023年に6億1,540万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは20.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.0％と17.6％と予測されています。欧州では、ドイツがCAGR約14.0%で成長すると予測されています。

世界のがん遺伝子治療市場- 主要動向と促進要因のまとめ

がん遺伝子治療ががん治療に革命をもたらす理由とは？

がん遺伝子治療は、がんとの闘いにおける画期的なアプローチであり、単に症状を治療するのではなく、がんの遺伝的な根本原因をターゲットにすることで革新的なソリューションを提供します。化学療法や放射線のような、健康な細胞とがん細胞の両方を攻撃する従来の治療とは異なり、遺伝子治療は、がんを発生させ、拡大させる原因となる遺伝子を変更または修復することを目的としています。この方法は、より正確で潜在的に害の少ない代替手段を提供します。CRISPR技術を用いた遺伝子編集や、ウイルスベクターによる治療用遺伝子の導入などの技術により、医師は変異した遺伝子を置き換えたり、がんと闘うのに役立つ新しい遺伝子を導入したり、がん細胞を免疫系に認識されやすくしたりすることができます。がん遺伝子治療のインパクトは治療だけにとどまらず、長期的な寛解をもたらし、場合によっては治癒をもたらすことさえあります。がんの遺伝的基盤を操作する能力は、治療へのアプローチ方法における記念碑的な転換を意味し、がん治療を画一的なモデルから、より個別化された効果的な戦略へと変貌させる。

技術の進歩はどのようにがん遺伝子治療を形成しているのか？

技術革新は、がん遺伝子治療の急速な進歩の原動力です。最近の動向で最も重要なのは、CRISPR-Cas9の台頭です。CRISPR-Cas9は遺伝子編集技術であり、科学者ががん細胞内の遺伝子を正確に改変することを可能にします。このツールはこの分野に革命をもたらし、研究者は突然変異を修正したり、がんの進行に寄与する遺伝子をノックアウトしたりすることができるようになった。治療用遺伝子をがん細胞に直接送り込むウイルスベクターも、ベクター工学の革新により、より効率的で安全なものになってきています。これらのベクターは、患者に害を与えることなく遺伝物質を細胞内に輸送する方法を提供するため、遺伝子治療において極めて重要です。さらに、次世代シークエンシング（NGS）は、個々のがんの原動力となっている遺伝子変異に関するより深い洞察を提供することで、がん遺伝子治療を進展させています。この技術により、患者のがん特有の遺伝子プロファイルに基づいた高度な個別化治療が可能になります。人工知能と機械学習もまた、大規模なデータセットを分析し、遺伝子治療介入の結果を予測することで極めて重要な役割を果たしており、効果的な治療法の設計を容易にしています。これらの技術的進歩は、遺伝子治療をより身近なものにしただけでなく、その安全性と有効性を向上させ、腫瘍学分野での成長を促進しています。

がん遺伝子治療における新たな動向と課題とは？

現在、がん遺伝子治療市場を形成しているいくつかの主要動向があり、それぞれがこの革新的治療法の拡大と改良に貢献しています。最も顕著な動向の一つは、個別化医療への注目の高まりです。がん遺伝子治療が遺伝的体質に基づいて個々の患者に合うようになるにつれて、業界はより良い治療結果を提供する高度にカスタマイズされた治療へとシフトしています。もう一つの動向は、免疫療法と遺伝子治療の併用が増加していることです。がん細胞を認識し破壊する免疫系の能力を強化することで、これらの治療法はさまざまながん種の治療においてより効果的で汎用性の高いものとなりつつあります。しかし、こうした進歩にもかかわらず、がん遺伝子治療はいくつかの課題に直面しています。重大な問題のひとつは、多くの患者やヘルスケア・システムにとって法外な治療費です。また、規制上のハードルや臨床試験の長いタイムラインなど、遺伝子治療開発の複雑さも、より広範な市場導入への課題となっています。さらに、オフターゲット効果や予期せぬ免疫反応のリスクが常に存在するため、遺伝子治療の安全性確保は依然として懸念事項です。このような障害にもかかわらず、技術革新の急速なペースとがん遺伝学に対する理解の深まりは、がん遺伝子治療の開発を推進し続けています。

がん遺伝子治療市場の主な成長促進要因は何か？

がん遺伝子治療市場の成長は、遺伝子編集技術の進歩、個別化医療への注目の高まり、世界のがん罹患率の上昇など、いくつかの要因によってもたらされます。最も大きな原動力の一つは、CRISPR-Cas9やその他の遺伝子編集技術のようなツールの開発であり、がん遺伝子治療の精度と有効性を大幅に向上させています。個別化医療の推進も大きな成長要因であり、より多くの患者やヘルスケアプロバイダーが、患者のがんを引き起こしている個々の遺伝子変異に合わせた治療を求めています。個別化された標的治療に対するこのような需要により、遺伝子治療の研究開発への投資が増加しています。さらに、世界のがんの有病率の上昇、特に高齢化社会におけるがんの増加は、長期的な解決策、あるいは治癒をもたらす革新的な治療法に対するニーズの高まりに寄与しています。免疫療法の進歩は、遺伝子治療によって免疫細胞を変化させ、がんと闘いやすくするもので、治療法の展望をさらに広げています。特定の遺伝子治療薬に対する規制当局の承認や画期的な指定は、市場への参入を加速させ、より迅速な導入を可能にしています。その結果、技術革新、個別化アプローチ、がん患者の増加が相まって、がん遺伝子治療市場の力強い成長が続いています。

調査対象企業の例（全42件）

  • Adaptimmune Therapeutics plc
  • Advantagene, Inc.
  • Altor Bioscience（a NANT Company）
  • Anchiano Therapeutics, Inc.
  • bluebird bio, Inc.
  • Genelux Corporation
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Shenzhen SiBiono GeneTech Co., Ltd.
  • ZIOPHARM Oncology, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP10864

Global Cancer Gene Therapy Market to Reach US$8.8 Billion by 2030

The global market for Cancer Gene Therapy estimated at US$2.3 Billion in the year 2023, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 21.1% over the analysis period 2023-2030. Oncolytic Virotherapy, one of the segments analyzed in the report, is expected to record a 21.9% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Gene Transfer Therapy segment is estimated at 15.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$615.4 Million While China is Forecast to Grow at 20.0% CAGR

The Cancer Gene Therapy market in the U.S. is estimated at US$615.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 20.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.0% and 17.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Cancer Gene Therapy Market - Key Trends and Drivers Summarized

Why Is Cancer Gene Therapy Revolutionizing Cancer Treatment?

Cancer gene therapy represents a groundbreaking approach in the fight against cancer, offering innovative solutions by targeting the genetic root causes of cancer rather than just treating the symptoms. Unlike traditional treatments like chemotherapy and radiation, which attack both healthy and cancerous cells, gene therapy aims to alter or repair the genes that cause cancer to develop and spread. This method provides a more precise and potentially less harmful alternative. Techniques such as gene editing, using CRISPR technology, or delivering therapeutic genes via viral vectors, allow doctors to replace mutated genes, introduce new genes that help fight cancer, or make cancer cells more recognizable to the immune system. The impact of cancer gene therapy extends beyond treatment, as it offers long-term remission and, in some cases, even a cure. The ability to manipulate the genetic foundation of cancer represents a monumental shift in how we approach treatment, transforming cancer care from a one-size-fits-all model to a more personalized and effective strategy.

How Are Technological Advances Shaping Cancer Gene Therapy?

Technological innovation is the driving force behind the rapid advancements in cancer gene therapy. The most significant development in recent years is the rise of CRISPR-Cas9, a gene-editing technology that allows scientists to precisely modify genes within cancer cells. This tool has revolutionized the field, enabling researchers to either correct mutations or knock out genes that contribute to cancer progression. Viral vectors, which deliver therapeutic genes directly into cancer cells, are also becoming more efficient and safer, thanks to innovations in vector engineering. These vectors are crucial in gene therapy as they provide a way to transport genetic material into cells without causing harm to the patient. Additionally, next-generation sequencing (NGS) is advancing cancer gene therapy by offering deeper insights into the genetic mutations driving individual cancers. This technology allows for highly personalized treatments based on the specific genetic profile of a patient’s cancer. Artificial intelligence and machine learning are also playing pivotal roles by analyzing large datasets and predicting the outcomes of gene therapy interventions, making it easier to design effective treatments. These technological advances have not only made gene therapy more accessible but have also improved its safety and efficacy, driving its growth in the oncology field.

What Are the Emerging Trends and Challenges in Cancer Gene Therapy?

Several key trends are currently shaping the cancer gene therapy market, each contributing to the expansion and refinement of this innovative treatment modality. One of the most prominent trends is the growing focus on personalized medicine. As cancer gene therapy becomes more tailored to individual patients based on their genetic makeup, the industry is seeing a shift towards highly customized treatments that offer better outcomes. Another trend is the increasing use of immunotherapy in combination with gene therapy. By enhancing the immune system's ability to recognize and destroy cancer cells, these therapies are becoming more effective and versatile in treating various cancer types. However, despite these advancements, cancer gene therapy faces several challenges. One significant issue is the high cost of treatment, which can be prohibitive for many patients and healthcare systems. The complexity of developing gene therapies, including regulatory hurdles and long timelines for clinical trials, also poses a challenge to broader market adoption. Additionally, ensuring the safety of gene therapies remains a concern, as there is always a risk of off-target effects or unwanted immune responses. Despite these obstacles, the rapid pace of innovation and growing understanding of cancer genetics continue to drive the development of cancer gene therapies.

What Are the Key Growth Drivers in the Cancer Gene Therapy Market?

The growth in the cancer gene therapy market is driven by several factors, including advances in gene editing technologies, the increasing focus on personalized medicine, and the rising incidence of cancer globally. One of the most significant drivers is the development of tools like CRISPR-Cas9 and other gene-editing technologies, which have greatly enhanced the precision and effectiveness of cancer gene therapy. The push towards personalized medicine is also a major growth factor, as more patients and healthcare providers seek treatments that are tailored to the individual genetic mutations driving a patient’s cancer. This demand for personalized, targeted treatments has led to increased investment in the research and development of gene therapies. Additionally, the rising prevalence of cancer worldwide, particularly in aging populations, is contributing to the growing need for innovative therapies that can offer long-term solutions or even cures. Immunotherapy advancements, where gene therapy is used to modify immune cells to better fight cancer, are further expanding the therapeutic landscape. Regulatory approvals and breakthrough designations for certain gene therapies are accelerating their entry into the market, allowing for faster adoption. As a result, the combination of technological innovation, personalized approaches, and increasing cancer cases continues to fuel the robust growth of the cancer gene therapy market.

Select Competitors (Total 42 Featured) -

  • Adaptimmune Therapeutics plc
  • Advantagene, Inc.
  • Altor Bioscience (a NANT Company)
  • Anchiano Therapeutics, Inc.
  • bluebird bio, Inc.
  • Genelux Corporation
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Shenzhen SiBiono GeneTech Co., Ltd.
  • ZIOPHARM Oncology, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Cancer Gene Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cancer Globally Spurs Growth in Demand for Cancer Gene Therapy
    • Advances in Genomic Research Throw the Spotlight on Precision Cancer Gene Therapies
    • Focus on Personalized Medicine Expands Addressable Market Opportunity for Gene-Based Cancer Treatments
    • Innovations in CRISPR and Gene Editing Propel the Development of Advanced Cancer Gene Therapies
    • Growing Investment in Gene Therapy Research Strengthens the Business Case for Novel Cancer Treatments
    • Shift Towards Targeted Therapy Accelerates Demand for Gene-Based Cancer Solutions
    • Expansion of Immunotherapy Techniques Sustains Growth in the Cancer Gene Therapy Market
    • Rising Interest in Oncolytic Virus Therapy Generates New Opportunities for Cancer Gene Therapy
    • Increasing Use of Next-Generation Sequencing Drives the Development of Precision Cancer Gene Therapies
    • Growing Focus on Rare and Aggressive Cancers Expands Market Potential for Gene Therapy Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer Gene Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oncolytic Virotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Gene Transfer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Gene-Induced Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • JAPAN
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • CHINA
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • EUROPE
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • FRANCE
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • GERMANY
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Rest of Europe 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Asia-Pacific 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of World 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030

IV. COMPETITION